TY - JOUR
T1 - Adherence to antidepressant therapy and mortality rates in ischaemic heart disease
T2 - Cohort study
AU - Krivoy, Amir
AU - Balicer, Ran D.
AU - Feldman, Becca
AU - Hoshen, Moshe
AU - Zalsman, Gil
AU - Weizman, Abraham
AU - Shoval, Gal
N1 - Publisher Copyright:
© 2015, Royal College of Psychiatrists. All rights reserved.
PY - 2015/4/1
Y1 - 2015/4/1
N2 - Background: The use of antidepressant drugs in patients with ischaemic heart disease (IHD) has been debated owing to scarcity of data and conflicting results regarding the effect of these drugs on mortality. Aims: To evaluate the association between adherence to antidepressant therapy and all-cause mortality in a population-based cohort of patients with IHD. Method: A total of 63 437 patients with IHD who purchased antidepressants at least once during the years 2008-2011 were retrospectively followed for all-cause mortality over 4 years. Adherence was measured as a ratio between claimed and prescribed durations of medication and modelled as non-adherence (<20%), poor (20-50%), moderate (50-80%) and good (>80%). We used multivariable survival analyses adjusted for demographic and clinical variables that may affect mortality. Results: The moderate and good adherence groups had significantly reduced adjusted mortality hazard ratios of 0.83 (95% CI 0.78-0.88) and 0.86 (95% CI 0.82-0.90) respectively, compared with the non-adherence group. Conclusions: Adherence to antidepressant pharmacotherapy is associated with reduced all-cause mortality in a population-based large sample cohort of patients with IHD. Physicians and health policy decision-makers should step up their efforts to sustain and enhance these patients' adherence to their antidepressant regimen.
AB - Background: The use of antidepressant drugs in patients with ischaemic heart disease (IHD) has been debated owing to scarcity of data and conflicting results regarding the effect of these drugs on mortality. Aims: To evaluate the association between adherence to antidepressant therapy and all-cause mortality in a population-based cohort of patients with IHD. Method: A total of 63 437 patients with IHD who purchased antidepressants at least once during the years 2008-2011 were retrospectively followed for all-cause mortality over 4 years. Adherence was measured as a ratio between claimed and prescribed durations of medication and modelled as non-adherence (<20%), poor (20-50%), moderate (50-80%) and good (>80%). We used multivariable survival analyses adjusted for demographic and clinical variables that may affect mortality. Results: The moderate and good adherence groups had significantly reduced adjusted mortality hazard ratios of 0.83 (95% CI 0.78-0.88) and 0.86 (95% CI 0.82-0.90) respectively, compared with the non-adherence group. Conclusions: Adherence to antidepressant pharmacotherapy is associated with reduced all-cause mortality in a population-based large sample cohort of patients with IHD. Physicians and health policy decision-makers should step up their efforts to sustain and enhance these patients' adherence to their antidepressant regimen.
UR - http://www.scopus.com/inward/record.url?scp=84928041620&partnerID=8YFLogxK
U2 - 10.1192/bjp.bp.114.155820
DO - 10.1192/bjp.bp.114.155820
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 25657353
AN - SCOPUS:84928041620
SN - 0007-1250
VL - 206
SP - 297
EP - 301
JO - British Journal of Psychiatry
JF - British Journal of Psychiatry
IS - 4
ER -